• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非相关医疗保健在获得的生命年数及一级预防的成本效益:探寻“完美”的成本效益比。

Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio.

作者信息

van Baal Pieter H M, Feenstra Talitha L, Hoogenveen Rudolf T, de Wit G Ardine, Brouwer Werner B F

机构信息

Centre for Prevention and Health Services Research (PZO), National Institute for Public Health and the Environment (RIVM), The Netherlands.

出版信息

Health Econ. 2007 Apr;16(4):421-33. doi: 10.1002/hec.1181.

DOI:10.1002/hec.1181
PMID:17039573
Abstract

An important subject of debate in cost-utility analysis of health care programmes is whether to include costs of unrelated medical care in life years gained. The inclusion of such costs is likely to be of consequence in the case of primary prevention. This paper presents different strategies regarding the inclusion not only of the costs, but also of the health effects of unrelated medical care in economic evaluations. Four different cost-utility ratios are presented and related to the criterion of internal consistency. In addition, the possibility to relate the ratios to a well-posed decision problem is analysed. An example computes the different ratios for smoking cessation interventions in different age groups. Including health care costs of unrelated medical care in life years gained increases cost utility ratios, but excluding unrelated medical costs favours smoking cessation interventions targeted at older smokers over those at younger smokers. We conclude that for primary prevention only a cost utility ratio that includes both the costs and effects of unrelated medical care meets the criterion of internal consistency and is related to a meaningful decision problem. Therefore, this type of cost-utility ratio should be preferred even if the data requirements may be substantial.

摘要

医疗保健项目成本效用分析中一个重要的辩论主题是,在计算获得的生命年数时是否应计入无关医疗护理的成本。在一级预防的情况下,计入此类成本可能会产生影响。本文提出了不同的策略,不仅涉及成本的计入,还涉及无关医疗护理的健康影响在经济评估中的计入。文中给出了四种不同的成本效用比,并将其与内部一致性标准相关联。此外,还分析了将这些比率与一个恰当决策问题相关联的可能性。一个例子计算了不同年龄组戒烟干预措施的不同比率。在计算获得的生命年数时计入无关医疗护理的医疗保健成本会提高成本效用比,但排除无关医疗成本则更有利于针对老年吸烟者的戒烟干预措施,而不是针对年轻吸烟者的措施。我们得出结论,对于一级预防而言,只有一种既计入无关医疗护理的成本又计入其影响的成本效用比符合内部一致性标准,并且与一个有意义的决策问题相关。因此,即使数据要求可能很高,这种类型的成本效用比也应优先选用。

相似文献

1
Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio.非相关医疗保健在获得的生命年数及一级预防的成本效益:探寻“完美”的成本效益比。
Health Econ. 2007 Apr;16(4):421-33. doi: 10.1002/hec.1181.
2
Economic evaluation and the postponement of health care costs.经济评估与医疗保健成本的推迟。
Health Econ. 2011 Apr;20(4):432-45. doi: 10.1002/hec.1599.
3
Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care.阐述将未来成本纳入经济评估的影响:终末期肾病护理的应用实例。
Health Econ. 2003 Nov;12(11):949-58. doi: 10.1002/hec.790.
4
Cost-effectiveness analyses of health promotion programs: a case study of smoking prevention and cessation among Dutch students.健康促进项目的成本效益分析:以荷兰学生预防和戒烟为例的研究
Health Educ Res. 2008 Apr;23(2):310-8. doi: 10.1093/her/cym024. Epub 2007 Aug 4.
5
Should the consumption of survivors be included as a cost in cost-utility analysis?幸存者的消费是否应作为成本效益分析中的一项成本包含在内?
Health Econ. 2004 May;13(5):417-27. doi: 10.1002/hec.850.
6
Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.伐尼克兰与安非他酮用于戒烟治疗的比较——2003年瑞典的成本效益结果
Respir Med. 2008 May;102(5):699-710. doi: 10.1016/j.rmed.2007.12.018. Epub 2008 Mar 4.
7
Costs and quality of life of multiple sclerosis in Switzerland.瑞士多发性硬化症的成本与生活质量
Eur J Health Econ. 2006 Sep;7 Suppl 2:S86-95. doi: 10.1007/s10198-006-0383-9.
8
Costs and quality of life in multiple sclerosis in The Netherlands.荷兰多发性硬化症的成本与生活质量。
Eur J Health Econ. 2006 Sep;7 Suppl 2:S55-64. doi: 10.1007/s10198-006-0378-6.
9
Costs and quality of life of multiple sclerosis in Italy.意大利多发性硬化症的成本与生活质量
Eur J Health Econ. 2006 Sep;7 Suppl 2:S45-54. doi: 10.1007/s10198-006-0385-7.
10
Costs and quality of life for patients with multiple sclerosis in Belgium.比利时多发性硬化症患者的成本与生活质量
Eur J Health Econ. 2006 Sep;7 Suppl 2:S24-33. doi: 10.1007/s10198-006-0377-7.

引用本文的文献

1
The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes.糖尿病不同模型下无关未来医疗成本对经济评估结果的影响。
Appl Health Econ Health Policy. 2024 Nov;22(6):861-869. doi: 10.1007/s40258-024-00914-z. Epub 2024 Sep 16.
2
Incorporating future unrelated medical costs in cost-effectiveness analysis in China.将未来无关医疗费用纳入中国成本效益分析。
BMJ Glob Health. 2021 Oct;6(10). doi: 10.1136/bmjgh-2021-006655.
3
Analysis of Anesthesia Methods in Percutaneous Kyphoplasty for Treatment of Vertebral Compression Fractures.
经皮椎体后凸成形术治疗椎体压缩性骨折的麻醉方法分析。
J Healthc Eng. 2020 Jan 9;2020:3965961. doi: 10.1155/2020/3965961. eCollection 2020.
4
Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients.纳入未来医疗成本:对癌症患者成本效益分析的影响。
Pharmacoeconomics. 2019 Jul;37(7):931-941. doi: 10.1007/s40273-019-00790-9.
5
Future Costs in Cost-Effectiveness Analyses: Past, Present, Future.成本效益分析中的未来成本:过去、现在、未来。
Pharmacoeconomics. 2019 Feb;37(2):119-130. doi: 10.1007/s40273-018-0749-8.
6
Single balloon versus double balloon bipedicular kyphoplasty: a systematic review and meta-analysis.单球囊与双球囊双侧后凸成形术治疗骨质疏松性椎体压缩骨折的系统评价和 Meta 分析。
Eur Spine J. 2018 Oct;27(10):2550-2564. doi: 10.1007/s00586-018-5631-z. Epub 2018 Jun 19.
7
Economic evaluation of health promotion interventions for older people: do applied economic studies meet the methodological challenges?老年人健康促进干预措施的经济评估:应用经济学研究是否应对了方法学挑战?
Cost Eff Resour Alloc. 2018 Apr 16;16:14. doi: 10.1186/s12962-018-0100-4. eCollection 2018.
8
Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease.哪些成本至关重要?经济评估中包含的成本及其对稳定型冠状动脉疾病决策不确定性的影响。
Pharmacoecon Open. 2018 Dec;2(4):403-413. doi: 10.1007/s41669-018-0068-1.
9
Is it Beneficial to Reuse the Balloon in Percutaneous Kyphoplasty for the Treatment of Non-Neoplastic Vertebral Compression Fractures?经皮球囊扩张椎体后凸成形术治疗非肿瘤性椎体压缩性骨折时再次使用球囊是否有益?
Med Sci Monit. 2017 Dec 13;23:5907-5915. doi: 10.12659/msm.905161.
10
Economic evaluation of health promotion for older people-methodological problems and challenges.老年人健康促进的经济评估——方法学问题与挑战
BMC Health Serv Res. 2016 Sep 5;16 Suppl 5(Suppl 5):328. doi: 10.1186/s12913-016-1519-y.